These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 28465155)

  • 1. Effect of Liver Disease on Hepatic Transporter Expression and Function.
    Thakkar N; Slizgi JR; Brouwer KLR
    J Pharm Sci; 2017 Sep; 106(9):2282-2294. PubMed ID: 28465155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver transporters in hepatic drug disposition: an update.
    Li P; Wang GJ; Robertson TA; Roberts MS
    Curr Drug Metab; 2009 Jun; 10(5):482-98. PubMed ID: 19689245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Hepatic Drug Transporters in Drug Development.
    Liu H; Sahi J
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S11-22. PubMed ID: 27385168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review.
    Laddha AP; Dzielak L; Lewis C; Xue R; Manautou JE
    Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167037. PubMed ID: 38295624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.
    Patel M; Taskar KS; Zamek-Gliszczynski MJ
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S23-39. PubMed ID: 27385177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of drug-metabolizing enzymes by local and systemic liver injuries.
    Guo Y; Hu B; Xie Y; Billiar TR; Sperry JL; Huang M; Xie W
    Expert Opin Drug Metab Toxicol; 2016; 12(3):245-51. PubMed ID: 26751558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.
    Canet MJ; Cherrington NJ
    Expert Opin Drug Metab Toxicol; 2014 Sep; 10(9):1209-19. PubMed ID: 24989624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Disease Pathologies on Transporter Expression and Function.
    Atilano-Roque A; Roda G; Fogueri U; Kiser JJ; Joy MS
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S205-21. PubMed ID: 27385176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sandwich-Cultured Hepatocytes for Mechanistic Understanding of Hepatic Disposition of Parent Drugs and Metabolites by Transporter-Enzyme Interplay.
    Matsunaga N; Fukuchi Y; Imawaka H; Tamai I
    Drug Metab Dispos; 2018 May; 46(5):680-691. PubMed ID: 29352067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of Hepatic Drug Transporters in Drug Disposition and Liver Toxicity.
    Pan G
    Adv Exp Med Biol; 2019; 1141():293-340. PubMed ID: 31571168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species.
    van Groen BD; Nicolaï J; Kuik AC; Van Cruchten S; van Peer E; Smits A; Schmidt S; de Wildt SN; Allegaert K; De Schaepdrijver L; Annaert P; Badée J
    Pharmacol Rev; 2021 Apr; 73(2):597-678. PubMed ID: 33608409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions.
    Bohan A; Boyer JL
    Semin Liver Dis; 2002; 22(2):123-36. PubMed ID: 12016544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.
    Varma MV; El-Kattan AF
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S99-S109. PubMed ID: 27385183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of New Chemical Entities as Substrates of Liver Transporters in the Pharmaceutical Industry: Response to Regulatory Requirements and Future Steps.
    Okudaira N
    J Pharm Sci; 2017 Sep; 106(9):2251-2256. PubMed ID: 28533120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
    Verbeeck RK
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1147-61. PubMed ID: 18762933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary hepatocyte cultures as prominent in vitro tools to study hepatic drug transporters.
    Ramboer E; Vanhaecke T; Rogiers V; Vinken M
    Drug Metab Rev; 2013 May; 45(2):196-217. PubMed ID: 23368091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic drug transporters: the journey so far.
    Riley RJ; Foley SA; Barton P; Soars MG; Williamson B
    Expert Opin Drug Metab Toxicol; 2016; 12(2):201-16. PubMed ID: 26670591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A perspective on efflux transport proteins in the liver.
    Köck K; Brouwer KL
    Clin Pharmacol Ther; 2012 Nov; 92(5):599-612. PubMed ID: 22948894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters.
    Kusuhara H; Sugiyama Y
    Drug Metab Rev; 2010 Aug; 42(3):539-50. PubMed ID: 20175646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug membrane transporters in the liver: regulation of their expression and activity].
    Fardel O; Payen L; Sparfel L; Vernhet L; Lecureur V
    Ann Pharm Fr; 2002 Nov; 60(6):380-5. PubMed ID: 12514503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.